Merck COVID Antiviral Does Not Reduce Risk Of Hospitalization, Death Rates In Vaccinated Individuals - Merck & Co (NYSE:MRK)
Published
According to a large study, dubbed PANORAMIC, Merck & Co Inc's (NYSE: MRK) COVID-19 antiviral molnupiravir speeds up recovery but does not reduce the hospitalization or death rate in higher-risk vaccinated adults. The study was conducted when the Omicron variant was dominant and compared the oral…
#merck #merckcoinc #omicron #molnupiravir #mrk